Stockscreener 앱 받기
36.72
1.58%
-0.63
Cytokinetics Inc 주식(CYTK)의 최신 뉴스
Cytokinetics Inc (CYTK) Q1 2025: Everything You Need To Know Ahead Of Earnings - GuruFocus
Why Cytokinetics, Inc. (CYTK) Went Down On Friday - Insider Monkey
10 Firms Battered by Poor Earnings, Dismal Outlook - Insider Monkey
Cytokinetics (CYTK) Target Price Lowered by UBS Analyst | CYTK S - GuruFocus
JMP reiterates $78 target on Cytokinetics stock, sees potential By Investing.com - Investing.com South Africa
CYTK Investors Have Opportunity to Join Cytokinetics, Incorporated Fraud Investigation with the Schall Law Firm - Business Wire
FDA Pushes Potential Approval For Cytokinetics' Experimental Heart Drug By Three Months - Benzinga
JMP reiterates $78 target on Cytokinetics stock, sees potential - Investing.com Australia
FDA Pushes Out Decision for Cytokinetics Heart Drug to Review Proposed Safety Plan - MedCity News
Cytokinetics (CYTK) Faces FDA Delay for Aficamten Approval - GuruFocus
Cytokinetics, Incorporated Investigated for Securities Fraud ViolationsContact the DJS Law Group to Discuss Your RightsCYTK - Business Wire
Cytokinetics reveals unexpected delay; AstraZeneca combo therapy hits in asthma - BioPharma Dive
Oh them REMS: Cytokinetics heart-hit with FDA delay - BioWorld MedTech
UBS Adjusts Price Target for Cytokinetics (CYTK) Amid Ongoing Challenges | CYTK Stock News - GuruFocus
Cytokinetics (CYTK): Needham Reiterates Buy Rating with $72 Targ - GuruFocus
UBS Adjusts Price Target on Cytokinetics to $41 From $47, Maintains Neutral Rating - marketscreener.com
Cytokinetics (CYTK) Faces Stock Drop After FDA Extends Drug Revi - GuruFocus
Cytokinetics stock falls on FDA delay for heart drug By Investing.com - Investing.com Canada
Cytokinetics stock drops on regulatory update (CYTK:NASDAQ) - Seeking Alpha
FDA Extends Review Period for Cytokinetics' (CYTK) Aficamten App - GuruFocus
FDA delays decision for Cytokinetics heart-failure drug - The Business Journals
FDA extends review period for Cytokinetics’ heart drug By Investing.com - Investing.com Canada
Cytokinetics Announces New PDUFA Date for Aficamten in Obstructive Hypertrophic Cardiomyopathy - The Manila Times
Cytokinetics Announces FDA Extension for Aficamten NDA Action Date to December 26, 2025 - Nasdaq
Barclays Initiates Coverage of Cytokinetics (BIT:1CYTK) with Overweight Recommendation - Nasdaq
Cytokinetics to Participate in May Investor Conferences - The Manila Times
Cytokinetics Leadership to Present at Citizens Life Sciences and RBC Healthcare Conferences - Stock Titan
Barclays Initiates Coverage of Cytokinetics (CYTK) with Overweight Recommendation - MSN
Cytokinetics gains as Barclays initiates bullish view on lead drug’s approval - MSN
Cytokinetics stock up on Barclays bullish view (CYTK:NASDAQ) - Seeking Alpha
This Cytokinetics Analyst Begins Coverage On A Bullish Note; Here Are Top 2 Initiations For Thursday - Benzinga
Cytokinetics (CYTK) Receives Overweight Rating as FDA Decision Nears | CYTK Stock News - GuruFocus
Barclays sets Cytokinetics stock overweight with $55 target By Investing.com - Investing.com Canada
Cytokinetics to Announce First Quarter Results on May 6, 2025 - The Manila Times
Cytokinetics Sets Q1 2025 Earnings Date: Key Biotech Financial Results Coming May 6 - Stock Titan
H.C. Wainwright maintains Buy on Cytokinetics stock, $120 target By Investing.com - Investing.com Canada
H.C. Wainwright maintains Buy on Cytokinetics stock, $120 target - Investing.com India
Bristol Myers Analyst Says FDA Update Is A Win For Camzyos With Simpler Use, Broader Reach - Benzinga
H.C. Wainwright maintains $120 target on Cytokinetics stock By Investing.com - Investing.com Canada
Bristol Myers' Camzyos Update Boosts Prospects for Cytokinetics (CYTK) | BMY Stock News - GuruFocus
Stifel maintains Cytokinetics stock buy rating, $87 target By Investing.com - Investing.com India
Stifel maintains Cytokinetics stock buy rating, $87 target - Investing.com
US FDA Expands Label For BMS’s Camzyos Days After Phase III Stumble - insights.citeline.com
Is Cytokinetics Inc. (NASDAQ:CYTK) the Best High Short Interest Stock to Buy Now? - Yahoo
10 Best High Short Interest Stocks to Buy Now - Insider Monkey
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Cytokinetics director John Henderson sells $123,325 in stock By Investing.com - Investing.com South Africa
Cytokinetics director John Henderson sells $123,325 in stock - Investing.com Australia
Bristol Myers Slumps On Heart Drug Failure — Taking Cytokinetics With It - MSN
Cytokinetics (CYTK) Gains Favor as Key Trial by Bristol-Myers Fa - GuruFocus
Camzyos nHCM Failure Could Open Door To Threat From Cytokinetics’ Aficamten - insights.citeline.com
JMP maintains $78 target on Cytokinetics stock after trial update By Investing.com - Investing.com Canada
Cytokinetics falls after rival Bristol Myers' heart drug fails trial - TradingView
BofA Adjusts Price Target for Cytokinetics (CYTK) Amid Competiti - GuruFocus
Bristol Myers stumbles in bid to widen heart drug’s use - Yahoo Finance
Citi Analysts Include Cytokinetics (CYTK) in 2025 North America Focus List | CYTK Stock News - GuruFocus
Imbria Pharmaceuticals: $57.5 Million (Series B) Raised To Develop Novel Therapies For Cardiometabolic Diseases - Pulse 2.0
0.35%
0.36%
자본화:
|
볼륨(24시간):